Raising the Bar: How Biotech Can Meet the Challenge

If the last decade in oncology often rewarded momentum, this conversation reflected a different operating reality. The bar is higher, the room is more skeptical, and “great science” is no longer assumed to be fundable on timelines that used to feel normal.

The shift is not philosophical. It shows up in fewer financings, narrower lanes, and a stronger penalty for strategies that cannot produce decision-grade proof early enough to sustain conviction.